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Abstract
Background: Long INterspersed Element-1 (LINE-1 or L1) is the only autonomously active, transposable element in
the human genome. L1 sequences comprise approximately 17 % of the human genome, but only the
evolutionarily recent, human-specific subfamily is retrotransposition competent. The L1 promoter has a bidirectional
orientation containing a sense promoter that drives the transcription of two proteins required for retrotransposition
and an antisense promoter. The L1 antisense promoter can drive transcription of chimeric transcripts: 5’ L1
antisense sequences spliced to the exons of neighboring genes.
Results: The impact of L1 antisense promoter activity on cellular transcriptomes is poorly understood. To
investigate this, we analyzed GenBank ESTs for messenger RNAs that initiate in the L1 antisense promoter. We
identified 988 putative L1 antisense chimeric transcripts, 911 of which have not been previously reported. These
appear to be alternative genic transcripts, sense-oriented with respect to gene and initiating near, but typically
downstream of, the gene transcriptional start site. In multiple cell lines, L1 antisense promoters display enrichment
for YY1 transcription factor and histone modifications associated with active promoters. Global run-on sequencing
data support the activity of the L1 antisense promoter. We independently detected 124 L1 antisense chimeric
transcripts using long read Pacific Biosciences RNA-seq data. Furthermore, we validated four chimeric transcripts by
quantitative RT-PCR and Sanger sequencing and demonstrated that they are readily detectable in many normal
human tissues.
Conclusions: We present a comprehensive characterization of human L1 antisense promoter-driven transcripts and
provide substantial evidence that they are transcribed in a variety of human cell-types. Our findings reveal a new
wide-reaching aspect of L1 biology by identifying antisense transcripts affecting as many as 4 % of all human
genes.
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Background
Our genome is replete with L1 retrotransposon-derived
sequences that can affect the transcriptome [1–3]. Gen-
omic L1 sequences propagate through RNA intermedi-
ates. Their lifecycle begins with transcription from the 5’
L1 promoter; this is followed by reverse transcription of
the L1 RNA and insertion of the L1 cDNA sequence
into the genome [1, 2]. There are two broad classes of
L1s. First is the less numerous class of full-length
(~6 kb) L1 retrotransposon sequences with intact in-
ternal promoters, of which there are approximately
7,000 copies in the human genome [4]. A subset of these
with intact coding sequences for open reading frame 1
protein (ORF1p) and ORF2p is potentially retrotranspo-
sition competent, and these elements are mostly specific
to our species (L1HS, or L1PA1 elements) [5]. Second is
the much more numerous and heterogeneous class of
mutated or truncated L1, which includes both species-
specific and ancient insertions. These insertions included
5’ truncations with or without internal rearrangements
at the time of their insertion. Depending on their length
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and mutation load these sequences may have no pro-
moter activity or protein-coding capability [1, 2, 6].
It is estimated that there are approximately 90
full-length, retrotransposition competent L1HS in the
human genome with intact internal promoters and
open-reading frames [5]. Additionally, 29 of the 362
full-length older L1PA2 are potentially active [6]. The
estimates are based on the length of the L1 insertions,
the integrity of their open reading frame sequences,
and results of in vitro retrotransposition assays that
may use an ectopic promoter to drive L1 expression.
However, sequence requirements for L1 promoter activity
have not been well defined.
Activity of the L1 antisense promoter (ASP) was first
demonstrated by Speek who described the discovery of
four chimeric L1 ASP transcripts, comprised of L1-
derived 5’-UTR and spliced exons from neighboring
single-copy genes [7]. Speek and colleagues also showed
that L1 ASP activity can drive tissue-specific transcrip-
tion of chimeric transcripts in a few instances [8, 9].
Subsequently, much work focused on the MET onco-
gene locus and the associated L1-MET chimeric tran-
script [10]. The L1-MET chimeric transcript initiates
within the second intron of the MET gene and down-
stream of the translational start site. Overexpression of
the L1-MET chimeric transcript causes decreased full-
length MET protein levels and MET-dependent signal-
ing perhaps through transcriptional interference [11].
Similarly, transcriptional derepression of the L1 chimeric
transcript LCT13 was linked to silencing of its cognate
transcript TFPI-2, a tumor suppressor in a variety of hu-
man malignancies [12].
In another approach to identify chimeric L1 ASP tran-
scripts, Cruickshanks and Tufarelli applied L1 chimera
display to identify eighteen novel chimeric L1 ASP tran-
scripts, some of which were selectively detected in breast
and colon cancer specimens but not in matched normal
tissues [13]. These investigators also showed that DNA
methylation limits the activity of L1 ASP in normal tis-
sues and that 5-aza-cytidine treatment of established
cancer cell lines causes expression of chimeric L1 ASP
transcripts [13]. Other studies have found evidence of
antisense expression in more ancient L1 elements. Macia
et al. found that more ancient primate L1 elements in-
cluding L1PA2-10 were capable of antisense transcrip-
tion [14]. Faulkner et al. identified transcription start
sites of cap-selected RNAs and found that L1 fragments
displayed antisense expression at the 3’ end of the L1
element [15].
The human-specific subfamily L1HS and the primate
specific subfamilies L1PA2-8 were identified to contain
an open reading frame termed ORF0 that is transcribed
downstream of the L1 ASP on the antisense strand [16].
The ORF0 is typically translated as a short peptide and
locates to promyelocytic leukemia-adjacent nuclear bodies
in the cytoplasm [16]. There are ~3200 genic loci encod-
ing L1 ORF0, which is typically encoded completely within
the L1 ASP sequence. A rare fraction, 57 of ~3200 L1
ORF0 loci, encodes a peptide where ORF0 was observed
to be fused to a gene exon [16].
Although the existence of L1 ASP transcripts is well-
documented, many questions remain. The extent to which
L1 chimeric antisense transcripts impact the human tran-
scriptome and what other genes may be under the influ-
ence of L1 ASP is unknown. The importance of these L1
ASP transcripts is further highlighted by the recent identi-
fication of ORF0, which suggests chimeric L1 gene fusion
transcripts might be expressed. Herein, we report the
identification and comprehensive characterization of 988
putative L1 ASP transcripts.
Results
Identification of many novel L1 ASP transcripts
We queried human expressed sequence tag (EST) gen-
ome alignments to identify ESTs incorporating part of
an L1 sequence in the ASP. First, we required that the
transcription start site (TSS) of a spliced human EST be-
gins in the antisense orientation relative to an annotated
L1 element and second, that a spliced exon of the EST
must also overlap an annotated exon of a gene. Third,
we removed putative L1 ASP transcripts where an inde-
pendent EST supported L1 exonization, rather than tran-
scription starting from within the L1 element. We
implemented the third criterion because ESTs are not
full-length transcripts and gene transcripts can retain in-
tronic L1s on the opposite strand because L1s contain
cryptic splice sites [17, 18]. We used BEDtools to con-
duct intersections and identified 2015 ESTs supporting
putative L1 ASP transcripts (Fig. 1a, Additional file 1:
Table S1). Only a small fraction of ESTs, 2.3 % or 46/
2015, was annotated by the UCSC-spliced human EST
database to map to multiple locations in the genome,
with at least one these locations not matching our cri-
teria. The 2015 ESTs map to exon sequences of 988
genes (Additional file 1: Table S1, Fig. 1b). We identified
45/89 previously known published L1 ASP transcripts
[7–9, 11–13, 16] and confirmed existence of 37/228 de-
posited on C-GATE [19], a publicly available project on
genes affected by transposable elements (Fig. 1b). The
vast majority, 911/988, of L1 ASP transcripts in our sur-
vey are novel. The ESTs supporting L1 ASP transcripts
were identified on every human chromosome, although
the Y chromosome that is gene poor displayed relatively
few chimeric transcripts (Additional file 2: Figure S1).
Properties of L1 ASP transcripts
Of the L1 ASP transcripts, 609 were represented by only
one EST, which suggests that many L1 ASP transcripts
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are transcribed at relatively low levels. The remaining
379 transcripts were represented by multiple ESTs
(Fig. 1c). The top three most widely expressed L1 ASP
transcripts were associated with CPM (99 ESTs), BCAS3
(49 ESTs), and DDX39B (42 ESTs). Interestingly, L1-
CPM has not been previously identified. We next anno-
tated the identified L1 ASP transcripts by the subfamily
of L1 that contained the ASP. Remarkably, we found
that, of the 2015 identified ESTs, only 52/2015, or 2.6 %
of all of the transcripts, originate from the evolutionarily
young L1HS subfamily (Fig. 2a, Additional file 2: Figure
S2). The vast majority, 626/2015 or 31.1 %, originate
from pre-Ta, primate-specific L1 subfamilies and 1337/
2015 or 66.3 % originate from older mammalian L1 sub-
families. The prevalence of evolutionarily ancient and
mutated L1s as a source of L1 ASP transcripts was un-
expected and suggests the possible exaptation of the L1
sequences over evolutionary time.
Next, we reviewed the primary tissues (1531 ESTs)
and cell lines (355 ESTs) that were sources of ESTs, and
categorized them as cancerous (578 ESTs) or normal
(1308 ESTs) (Table S1). Some ESTs could not be charac-
terized due to a lack of supporting information. Interest-
ingly, 69.4 % of ESTs supporting an L1 ASP transcript
originated from non-cancerous tissues (Fig. 2b). For
ESTs derived from cancerous tissue, the most prevalent
sources were embryonic carcinoma cells (NT2 testis em-
bryonal carcinoma cell line), head/neck tissue (tongue
tumor), and fibrosarcoma cells (HT1080 fibrosarcoma
cell-line) (Fig. 2c). L1 ASP transcripts in normal tissue
were primarily identified from brain or testis tissues.
Our analysis supports the notion that L1 ASP transcripts
are readily detectable in both normal and diseased states.
However, due to source tissue biases in the EST data-
base, we cannot conclude the L1 ASP promoter activity
is higher overall in the brain or testis. Finally, we con-
ducted a gene ontology (GO) analysis of the 988 cognate
genes that contained putative L1 ASP transcripts. The
results of our GO analysis showed overrepresentation of
genes involved in diverse cellular processes including
vesicle-mediated transport, intracellular protein trans-
port, mitosis, morphogenesis, and protein modifications
(Additional file 3: Table S2).
We next examined the relationship of ESTs supporting
L1 ASP transcripts to their overlapping cognate genes.
Some of the 2015 ESTs overlapped multiple genes; in
total, we identified 2316 pairwise overlaps between the
ESTs and an annotated gene exon. We found that the
vast majority of chimeric transcripts, 2134/2316 or
92.1 %, were sense to the nearby gene, a proportion that
was highly statistically significant (p-value, < 2.2*10−16,
chi-squared test); on the contrary, only 182/2316 or
Fig. 1 Identification of novel L1 antisense promoter (ASP) transcripts using a computational pipeline. a Schematic representation of our method to
identify L1 ASP transcripts. The coordinates of human spliced ESTs were intersected with L1s and gene exons to identify ESTs with a TSS antisense to
an L1 and overlapping an exon of a cognate gene. L1 ASP transcripts that displayed an independent EST supporting L1 exonization were removed.
b Total number of L1 ASP transcripts identified in the current report (n = 988) cross-referenced to known existing L1 ASP transcripts found in published
reports including recently identified L1 ORF0 gene fusions and the C-GATE database. c Histogram of the total number of ESTs identified per gene for
L1 ASP transcripts (n = 2015 ESTs, some overlapping multiple genes)
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7.9 % were in the antisense orientation. We examined
the distance from the EST transcription start site (TSS)
to the TSS of the cognate gene in these two categories.
The L1 ASP transcripts sense to their cognate genes was
typically downstream of the gene TSS. Thus, the L1 pro-
vides an alternative start site and produces a transcript
in which the annotated 5’UTR or first coding exon is
not included (Fig. 3a, b left panels). All of the L1 ASP
transcripts that were on the strand opposite from the
cognate gene were downstream of the gene TSS (Fig. 3a,
b right panels). This minor category of L1 ASP tran-
scripts extended and overlapped antisense to the exon of
the cognate gene.
To further validate L1 ASP transcripts we examined
publicly available long-read RNA-seq data from human
embryonic stem cells (H1-ESCs) sequenced using a
Pacific Biosciences (PacBio) instrument [20]. The RNA-
seq reads generated by PacBio are long (averaging 2–
3 kb length), but are lower quality. Therefore, Au K. et
al. error corrected the long-read PacBio RNA-seq reads
using short read Illumina RNA-seq data [20]. Subse-
quently, the error corrected long RNA-seq data was used
for isoform detection by Au K. et al. to identify
expressed transcripts in H1-ESCs [20]. We used the
publicly available transcript isoform prediction for H1-
ESCs to validate L1 ASP transcripts identified by our
EST screen. We were able to validate 124/988 or 12.6 %
of the L1 ASP transcripts reported here as expressed in
H1-ESCs (Fig. 3b, Additional file 1: Table S1). Thus,
using low coverage RNA-seq data from a single cell-line
we were able to independently validate 12.6 % of the L1
ASP transcripts we identified.
Next we sought to address the coding potential of L1
ASP transcripts because the majority was sense to the
cognate gene and could potentially contain open reading
frames (ORFs). We applied TransDecoder software to
identify putative peptides encoded by ESTs with at least
100 amino acids (aa) [21]. We also required that the pre-
dicted putative peptide begin with a start codon encod-
ing methionine and identified that 546/2015 or 27.1 % of
the ESTs contained the potential for coding putative
peptides (Fig. 3b). The identified putative peptides
ranged from 100 to 268 aa, with an average putative
peptide length of 140 aa (Additional file 4: Table S3,
Fig. 3b). Of the identified putative peptides 42 contained
fragments of the recently identified ORF0 open reading
frame protein [16]. However, because we only included
spliced ESTs and ORF0 is contained within the unspliced
5’ UTR of L1HS we did not identify a full-length ORF0
[16]. However, it is important to note that in the absence
of additional experimental data these are only peptide
predictions. In summary, L1 ASP transcripts are
Fig. 2 L1 subfamily and tissue distributions of L1 ASP transcripts. a Evolutionary age of L1 subfamilies indicates a role for most L1 evolutionary subtypes in
genesis of L1 ASP transcripts. b Characterization of source material used for ESTs cDNA that support L1 ASP transcripts. c Tissue source for ESTs supporting
L1 ASP transcripts identified in hyper-proliferative or cancerous samples. d Normal tissue sources for ESTs used to identify L1 ASP transcripts
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predicted to contain putative peptides that extend from
the L1 ASP into cognate genes.
Characterization of the L1 ASP
Next we compared the L1 ASP transcription start sites
to the L1 consensus sequences. We aligned the 2015
ESTs supporting L1 ASP transcripts to full-length con-
sensus sequences in RepBase and those reported by
Khan et al. [4]. We divided the L1s by evolutionary age,
examining the most recent human L1HS, less recent pri-
mate L1PA2-8, more ancient primate L1, and ancient
mammalian L1 subfamilies. We observed that the ESTs
mapping to L1HS elements aligned within the first
600 bp of the 5’ UTR antisense to the L1 consensus se-
quence (Fig. 4a). The locations of the L1HS antisense
TSS within the 5’ UTR were consistent with prior de-
scriptions of L1 ASP transcripts [7]. Recent primate
L1PA2-8 elements that are highly homologous to L1HS
Fig. 3 Most L1 ASP transcripts are sense to cognate genes and possess protein coding potential. a L1 ASP transcripts tend to be in sense strandedness
relative to the cognate gene, typically serving as an alternative TSS of the canonical gene TSS (left panel). Rarely, ESTs supporting L1 ASP transcripts overlap
anti-sense to cognate gene (right panel). The bias towards sense-strandedness of L1 ASP transcripts suggested the possibility for protein coding potential.
ESTs supporting L1 ASP transcripts that had multiple alignments in the database (~2.3 % of all ESTs) were excluded. b Independent analysis of long-read
PacBio RNA-seq data identified transcript isoforms supporting 124/988 L1 ASP transcripts. We validated both instances where the L1 ASP transcript was
sense to the cognate gene (L1-PPP1R1C, left panel). We also validated the opposite strand L1 ASP transcript (L1-ABCA9, right panel). The red indicates the
positive strand and the blue indicates the negative strand for the genome browser view. c Coding potential of L1 ASP transcripts was assessed by the
ability to encode an open reading frame (ORF) of at least 100 amino acids (aa) and to begin with a start codon. We identified that 27.1 % of ESTs contained
the potential for coding by these criteria
Criscione et al. BMC Genomics  (2016) 17:463 Page 5 of 15
in the 5’ UTR [22] also displayed L1 ASP activity in an
identical location to L1HS (Fig. 4a). However, older pri-
mate L1s and ancient mammalian L1s displayed only
minor L1 antisense activity in the 5’ UTR and the major-
ity of activity was in the 3’ end of the element overlap-
ping ORF2 (Fig. 4a). Our result is consistent with a prior
report demonstrating that L1 fragments display ASP ac-
tivity at the 3’ end of the element [15].
We further interrogated ESTs from recent primate
L1PA2-8 subfamilies and the human L1HS subfamily for
transcription factors that might drive transcription from
the ASP [22]. YY1 is the best characterized cis-
regulatory transcription factor proposed to be required
for L1 transcription from the sense promoter [23]. YY1
was previously reported to bind between 13 and 21 bp
of L1HS 5’ UTR on the antisense strand [23–26]. Inter-
estingly, YY1 is also an important regulator of bidirec-
tional transcription at the promoters of multiple single-
copy genes [27, 28]. To examine the possibility that YY1
could play a role in the L1 ASP, we sought to better
characterize YY1 binding to the L1HS 5’ UTR. First, we
applied JASPAR Scan to examine the 5’ UTR of the
L1HS consensus sequence for YY1 transcription factor-
binding sites using a relative score of at least 90 % [29].
We identified five putative binding sites based on YY1
position weight matrices, including two that overlapped
the proposed binding site (13 to 21 bp) and three add-
itional binding sites (Additional file 5: Table S4). Next,
we examined YY1 transcription factor binding to the
L1HS consensus sequence using ChIP-seq data available
for YY1 from the ENCODE project [30]. For all of the
ENCODE cell lines, we identified two peaks that dis-
played enrichment for YY1: the first, Peak-1, corre-
sponded to the known YY1 binding site at ~20 bp; the
second, Peak-2, was at ~450 bp in the L1HS 5’ UTR
(Fig. 4b). Peak-2 overlaps closely with an identified
Fig. 4 Features of the L1 antisense promoter revealed from ESTs, ENCODE ChIP-seq, and GRO-seq data. a ESTs supporting alternative L1 ASP transcripts
for L1HS, L1PA2-8, ancient primate L1, and ancient mammalian L1 subfamilies were aligned to full-length L1 consensus sequences. The plot revealed
evolutionarily recent L1HS and L1PA2-8 subfamilies possess the ASP activity in the 5’ UTR, whereas ancient primate and ancient mammalian L1 subfamilies
display minor ASP activity in the 5’ UTR and the majority is at the 3’ end of the element overlapping the end of ORF2. b YY1 enrichment profile in the
5’UTR of L1HS consensus sequence for ENCODE YY1 ChIP-seq in various cell-lines. The schematic above is a reference point to the L1HS consensus
position. c The TSS enrichment profile for YY1, H3K9me2, and H3K9me3 ChIP-seq for L1HS and L1PA2-8 AS ESTs in units of input subtracted reads per
million mapping reads (RPM) using the K562 cell-line. The bottom panel displays the GRO-seq TSS enrichment profile in RPM enrichment units. The
schematic above is a reference point to the L1HS consensus position
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putative YY1 binding site on the positive strand at 448
to 453 bp, which immediately precedes the primary L1
ASP at ~400 bp. (Fig. 4a-b). The secondary binding site
of YY1 near the primary L1 ASP suggests that YY1 may
play a role in regulating L1 antisense transcription.
To test whether TSS locations of L1 ASP transcripts
were bound by YY1 and marked by histone modifica-
tions, we examined ENCODE ChIP-seq alignments to
the human genome (build hg19). We reviewed ChIP
data for YY1, H3K4me2, and H3K4me3 histone modifi-
cations in the K562, H1-ESC, and Hela cell-lines [30].
The histone modifications H3K4me2 and H3K4me3 are
typically associated with euchromatic, active or poised
promoters [31–34]. We found that the ESTs supporting
L1 ASP transcripts displayed modest enrichment for
YY1 at the TSS in ENCODE (Fig. 4c, Additional file 2:
Figure S3). Peak-2 for YY1, identified in Fig. 4b, directly
overlapped near the TSS of the ESTs supporting L1 ASP
transcripts. Immediately downstream of the TSS, based
on transcription orientation, we identified modest en-
richment for histone marks H3K4me2 and H3K4me3 in
K562, H1-ESC, and Hela cell-lines (Fig. 4c, Additional
file 2: Figures S4A-B). We next examined global run-on
sequencing (GRO-seq) data, a high-throughput nuclear
run-on assay that can identify 5’-capped RNAs [35–37].
We found that GRO-seq sequencing reads were mapped
to the TSS of the majority of L1 antisense ESTs in K562,
MCF7, and Hela cell-lines (Fig. 4c, Additional file 2:
Figures S4C-D). Together, this data supports that YY1
binds to the L1 ASP in addition to the previously char-
acterized binding site near the sense promoter. Add-
itionally, analysis of histone modifications associated
with active or poised promoters and GRO-seq data sug-
gests that the L1 ASPs we identified are likely to be ac-
tively transcribed in a variety of cell types.
Validation of L1 ASP transcripts
We selected two genes associated with L1 ASP tran-
scripts for Sanger sequence-based confirmation. We
successfully detected L1 ASP transcripts associated with
both KIAA1324L and UVRAG genes (Fig. 5a-b,
Additional file 6: Table S5). Sanger sequenced reads
across L1-KIAA1324L and L1-UVRAG transcripts re-
vealed that L1 antisense was fused in frame to
KIAA1324L and UVRAG. We compared our list of
genes associated with L1 ASP transcripts to the genes
causally implicated in human malignancies annotated by
the COSMIC database [38, 39]. We identified 20 impli-
cated causal cancer-associated genes with L1 ASP tran-
scripts, including L1-MET, L1-JAK1, L1-NF1, L1-
PRKAR1A, and L1-RHOA (Additional file 7: Table S6).
Apart from L1-MET and L1-CBFA2T3, the other 18
cancer-associated L1 ASP transcripts have not previously
been described. Interestingly, L1-NF1 expression in normal
human tissues closely resembled the expression of cognate
cancer-associated gene NF1 (Fig. 6a). The validation of the
Fig. 5 Validation of selected L1 ASP transcripts by combined PCR and Sanger-sequencing methods. a Upper panel: Genome browser view of
KIAA1324L genomic locus displaying the ESTs supporting L1- KIAA1324L. Middle panel: Representative PCR product obtained by PCR amplification
with L1-specific primer and KIAA1324L-specific primer. Lower panel: selected Sanger sequencing read across L1 to KIAA1324L exon 1 boundary;
blue letters denote L1 AS promoter sequence, orange letters denote KIAA1324L exon 1 sequence. b Empirical validation of L1-UVRAG, with same
orientation as Figure 5a
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L1 antisense transcript for SEC22B also showed that the
transcript was expressed at levels near wild-type cog-
nate SEC22B transcripts (Fig. 6d). The L1-SEC22B and
L1-NF1 were each supported by one EST, whereas ~118
and ~771 spliced ESTs corresponded to the wild type
SEC22B and NF1 transcript, respectively. The discrep-
ancy between EST ratios and quantitative RT-PCR re-
sults can be explained by the heterologous mixture of
tissues and cDNA library size used as source material
for ESTs. Many ESTs supporting the wild-type tran-
scripts have identical alignment coordinates and are
from the same cDNA library. These issues complicate
the quantitation of EST ratios and make comparison of
these ratios to the quantitative RT-PCR results difficult
to interpret. Although we note this discrepancy, the val-
idation of 4/4 L1 ASP transcripts by quantitative RT-
PCR and Sanger sequencing supports that the screen
identified many new and undescribed chimeric tran-
scripts that are driven by the L1 ASP.
L1 ASP transcripts overlapping L1 exonized transcripts
The method to identify L1 ASP transcripts implemented
a criterion to remove ESTs where an independent EST
suggested L1 exonization (e.g., inclusion of an intronic
L1 on the opposite strand within a normal gene tran-
script). We examined this category in more detail and
report these putative transcripts separately (Additional
file 8: Table S7). Many of these events cannot be unam-
biguously assigned as an L1 antisense transcript due to
the presence of an EST also supporting L1 exonization.
However, we observed transcripts where the majority of
ESTs supported L1 ASP driven transcription rather than
L1 exonization (including MAPK10, Additional file 2:
Figure S5A). We also observed events where ESTs
supporting L1 ASP driven transcripts and ESTs support-
ing L1 exonization were non-overlapping (including
SCAMP1, Additional file 2: Figure S5B). Therefore, in
some cases L1s might contribute both to L1 ASP driven
transcripts and L1 exonized transcripts.
Identification of mouse L1 ASP transcripts
In the mouse genome LINE-1 elements are also active,
yet they are quite different from the human L1HS sub-
family at the sequence level. Nevertheless, active mouse
LINE-1 elements contain an L1 ASP also capable of
yielding fusion transcripts [40]. Unlike the human L1HS
subfamily, which contains the L1 ASP in the 5’ UTR, the
mouse ASP is within the first open reading frame
(ORF1p) [40]. We applied our bioinformatic approach to
identified spliced ESTs consistent with an L1 antisense
transcript in the mouse genome. The results for the
mouse are an underestimate because unlike human ESTs
Fig. 6 L1 driven transcripts are expressed in many normal human tissues. a-b Tissue specific expression levels of L1 ASP transcripts L1-NF1 and
L1-SEC22B relative to wild-type cognate genes, respectively. Upper panel: Genome browser view of genomic locus displaying the ESTs supporting
L1 ASP transcripts. Lower panel: Quantitative RT-PCR results of L1 ASP transcripts and cognate wild type gene in 9 tissues
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many of the mouse ESTs in the spliced alignment data-
base did not contain transcript orientation. However,
despite our strict filtering we identified L1 ASP tran-
scripts for 174 cognate genes that were supported by
307 ESTs (Additional file 9: Table S8). Of the 174 identi-
fied L1 ASP transcripts 23 corresponded to the mouse-
specific LINE-1 retrotransposon subfamilies (L1Mus1-4).
Surprisingly, we again identified a subset of evolutionar-
ily ancient L1 subfamilies that were transcribing an L1
antisense transcript, which we also identified in human.
The L1 ASP transcript SHISA5 was identified within
both the human and mouse genomes transcribed anti-
sense to shared mammalian L1M5 (Additional file 2:
Figure S6).
Discussion
Here, we present one of the most comprehensive studies
of L1 ASP transcripts in the human genome. We de-
scribe in total 988 chimeric transcripts of which 911 are
novel, where the L1 ASP drives the expression of a tran-
script that is spliced to a gene exon; and they are collect-
ively supported by 2015 ESTs. Because we required
evidence of splicing at the alignment level, our identified
L1 antisense ESTs correspond to processed transcripts.
Thus, the number of putative transcripts is almost cer-
tainly an underestimate. This is supported by the fact
that other published studies using complementary ap-
proaches identified 44 additional putative L1 ASP tran-
scripts we did not recover.
The L1 sense promoter has higher transcriptional ac-
tivity in many cancers, and increased L1 ORF1 expres-
sion and protein abundance is often observed [41, 42].
High levels of L1 somatic retrotransposition are also
readily detectable in a variety of cancers and during the
early stages of tumorigenesis [43–49]. We identified
20 L1 ASP driven transcripts that affect cancer genes,
including previously reported L1-MET [11]. While we
expected to identify an increased number of L1 ASP
transcripts from cancer specimens, the majority of ESTs
found in this survey were identified in normal tissues.
This is unlikely due to a bias in the EST database, which
contains a preponderance of cDNAs from cancerous tis-
sue and diseased states. Our analysis revealed that the
brain, testis, placenta, embryonic tissues, and lungs were
the most abundant contributors of ESTs supporting L1
antisense transcription.
About 27 % of the L1 ASP transcripts we describe
occur in the sense orientation to the cognate gene and
are predicted to produce a peptide of at least 100 amino
acids in length. Whether L1 ASP transcripts yield trans-
lated proteins remains an open question. However, re-
cent characterization of ORF0 and 57 instances of ORF0
gene exon fusions supports that a subset of transcripts
identified here are likely translated [16]. Interestingly,
some L1 ASP transcripts seem to match an annotated
gene transcript; in those cases the gene TSS starts in the
L1 ASP, an example being UVRAG.
In contrast, about 73 % of the L1 ASP transcripts are
not predicted to encode a putative peptide by our
metric. The absence of a predicted putative peptide of
100 amino acids has been previously used to define a
transcript as a long non-coding (lnc) RNA [50–52].
However, although atypical, some proteins with less than
100 amino acids reside in mammalian genomes [53]. An
important example of a short peptide that would not be
identified by this analysis is ORF0, which is only 71
amino acids [16]. Hence, our putative peptide prediction
does not preclude the possibility that additional L1 ASP
transcripts are potentially protein coding. In addition,
because our identification is based on ESTs, which are
not typically full-length transcripts, our current list
might represent an underestimate of L1 ASP transcript
putative predicted peptides.
We also describe L1 ASP transcripts incorporating
gene sequences in the antisense orientation. Such tran-
scripts are rare, comprising less than 8 % of our total,
but may be biologically important. Where expressed,
these have the potential to produce double-stranded
RNAs because they encode a transcript with reverse
complementarity to a portion of the cognate mRNA (for
example, RABL2B in Additional file 1: Table S1). The
dsRNA may impact epigenetic regulation at the locus
and the stability of the mRNA [54].
Nearly all of the L1HS and L1PA2-8 antisense ESTs,
subfamilies with a homologous 5’ UTR, display ASP ac-
tivity within the first 600 bp of the L1 5’ UTR, whereas
more ancient primate and mammalian L1s display the
majority of ASP activity at the 3’ end of the element near
the end of ORF2. This observation explains a previous
result indicating that L1 fragments display ASP activity
at the 3’ end of the L1 element [15]. In addition, this re-
sult clarifies how the majority of ancient L1s, which are
typically 5’ truncated, can contribute the majority of L1
ASP activity. We identified substantial evidence that L1
ASPs are transcriptionally active. There was binding of
regulatory elements including the transcription factor
YY1 at the L1 ASP. The transcription factor YY1 dis-
played a double peak binding distribution within the L1
promoter. YY1 transcription factor peak-1 in Fig. 4-c
corresponds to the position of the L1 sense promoter
and has been described previously [23]. YY1 transcrip-
tion factor peak-2 is newly identified and seems to over-
lap the position of the L1 ASP; however, binding of YY1
to peak-2 does not necessarily indicate a functional role.
Unlike YY1 the GRO-seq and histone mark ChIP-seq
profiles display a single peak distribution within the L1
promoter (Fig. 4c). The single GRO-seq peak overlaps
YY1 peak-2 at the site which is likely the TSS for the L1
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ASP. The predicted TSS position is also marked down-
stream by histone modifications H3K4me2 and H3K4me3
which is characteristic of active promoters. The GRO-seq
profiles are consistent with 5’ capped RNAs initiating from
this L1 ASP TSS. Whether the YY1 peak-2 is required for
L1 ASP transcription at the identified TSS warrants further
investigation. Independent validation of 124/988 L1 ASP
transcripts using PacBio long read RNA-seq suggested ex-
pression of a large subset of identified transcripts in embry-
onic stem cells. Together, several lines of evidence indicate
these transcription start sites function as active promoters.
The L1 ASP was likely active at multiple points in mam-
malian evolution. While ancient subfamilies are no longer
competent for retrotransposition they are contributing to
the transcriptome through promoter activity. Similarly, in
the mouse, L1_Mus1-4 subfamilies also contribute to new
L1 ASP transcripts. The mouse element contains the ASP
in ORF1p [40]. While the sequence differs dramatically be-
tween human and mouse L1s, the functional conservation
of ASP activity indicates selective pressure to preserve this
feature. It is interesting to speculate as to whether the L1
ASP activity benefits the host or the L1 element fitness.
There is some evidence that the L1 ASP transcripts might
produce siRNAs to repress the L1 sense transcript [55].
Contradicting this view is new evidence that ORF0 tran-
scribed from the ASP is correlated with the transposition
competent sense transcript [16]. Lastly, there are more in-
stances being identified of transposons being exapted for
normal cellular functions by the host [56]. The fact that
some ancient mammalian L1 elements are conserved in di-
verse mammals from human to mouse provides support to
the hypothesis that L1 ASP transcripts may be exapted for
functional roles.
Perhaps one of the most interesting and easily testable
ramifications stemming from identification of such a
large number of L1 ASP transcripts is that some are
likely to be polymorphic in the human population. Some
of the transcripts identified here are likely to be absent
in at least some individuals in the human population. By
extension, there are likely polymorphic L1 transposition
events present in the population but absent from the ref-
erence genome that would also likely contribute to L1
ASP transcripts. It would be of interest to determine al-
lele frequency for a handful of chosen L1 ASP tran-
scripts. For instance, is the putative L1-MET chimeric
transcript polymorphic, and does it segregate with any
observable phenotype? The expanded repertoire of L1
ASP transcripts described herein could exert numerous
effects on gene regulation that remain to be investigated.
Methods
Computational detection of putative L1 ASP transcripts
We identified candidate L1 ASP transcripts by applying
a series of intersections on genomic intervals of three
annotations obtained using the UCSC table browser tool
in Browser Extensible Data (BED) format. First, we
downloaded the locations of L1 elements by extracting
the coordinates of all LINE-1 family repeats from the
Repeatmasker (hg19) annotation [57]. Second, we down-
loaded the annotated exon coordinates of RefSeq genes
(hg19). Third, we downloaded the coordinates of UCSC
human spliced ESTs, a table containing the alignment
coordinates of ESTs displaying evidence of splicing, as a
block feature (start to end) and as coordinates of spliced
EST exons (downloaded July 2015). Importantly, the
strand field in the UCSC human spliced ESTs table re-
flects the alignment direction (e.g., plus is 5’ to 3’) of the
EST cDNA to the genome by Blat and does not reflect
the transcriptional direction. To convert the strand in
the UCSC human spliced ESTs database to reflect tran-
scriptional direction, we used the linked UCSC estOrien-
tInfo table. If the value of the intronOrientation field in
the associated table is positive, the transcriptional direc-
tion matches the alignment direction; however, if the
intronOrientation field is negative, the strandedness is
opposite. Sometimes, a call cannot be determined for
EST transcriptional direction because the intronOrienta-
tion field is zero; these ambiguous cases were removed
manually from subsequent analyses. For mouse we used
a similar set of annotations: Repeatmasker (mm10),
RefSeq genes (mm10), and the UCSC mouse spliced
ESTs (mm10, downloaded July 2015). For the mouse an-
notation, a larger fraction of cases were ambiguous and
removed because the intronOrientation field was zero
and transcriptional direction could not be determined.
Next, we defined criteria to identify putative L1
ASP transcripts. The 5’ TSS of the EST was required
to originate from within an annotated L1 element,
and the transcriptional direction strand of the EST
was required to be antisense to the L1. Second, an
exon coordinate of the EST was required to overlap
with an annotated exon coordinate of a gene. Third,
we excluded L1 ASP transcripts where an independ-
ent EST supported L1 exonization (e.g., inclusion of
an intronic antisense L1 in a gene transcript of the
structure exon to L1 to exon). We selected ESTs
that met this criteria and represented L1 ASP tran-
scripts using sequential intersections performed with
bedtools [58]. To verify the accuracy of the selection
method, we manually inspected putative L1 ASP
transcripts using the UCSC genome browser. Manual
inspection identified a subset of ESTs that contained
a higher degree of uncertainty due to the presence
of multiple annotated alignments. We subsequently
added whether the UCSC human spliced ESTs con-
tained more than one alignment of the EST to
Additional file 1: Table S1, in order to distinguish
this category.
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Computational validation with PacBio RNA-seq
The long-read PacBio RNA-seq data from human em-
bryonic stem cells (H1-ESCs) was annotated as tran-
script isoform predictions by Au, K. et al. [20]. We
downloaded H1-ESCs transcript isoform predictions in
GTF format and converted the data to BED format. We
applied the same intersections as described above for the
EST screen using BEDtools. We characterized the fil-
tered set of PacBio transcript isoforms for those also
identified by the EST screen that supported L1 ASP
transcripts.
Annotation of ESTs that support L1 ASP transcripts
Additional information on tissue of origin, cell line of
origin, and normal/cancer status were obtained by
extracting and parsing associated information on ESTs
downloaded from the Batch Entrez portal (http://
www.ncbi.nlm.nih.gov/sites/batchentrez), which was
then added to Additional file 1: Table S1. The ESTs sup-
porting putative L1 ASP transcripts may be represented
multiple times in Additional file 1: Table S1 because they
overlap with more than one gene; however, further data
analysis was only conducted on the unique set of ESTs
identified. We manually inspected 554 of the identified
ESTs using the UCSC genome browser and verified they
all matched the above criteria for an L1 ASP transcript
in at least one location. The EST sequences of all identi-
fied putative L1 ASP transcripts were also downloaded
in FASTA format using the Batch Entrez portal. The se-
quences were examined for the presence of open reading
frames (ORFs) of at least 100 bp using the TransDecoder
module (http://transdecoder.github.io/) of Trinotate
Transcript Annotation, which is a part of the Trinity
package [21]. We also required that predicted ORFs start
with a start codon encoding methionine to be consid-
ered a putative peptide. The genes associated with pu-
tative L1 ASP transcripts were used for gene ontology
analysis using the PANTHER online statistical overrep-
resentation test [59] and the PANTHER GO slim
biological process (with redundant GO categories re-
moved). The raw p-values for the full results reported
by PANTHER were corrected using Benjamini Hochberg
false discovery rate correction using the R statistical
language [60].
Characterization of the L1 ASP
We examined L1 ASP transcripts in four categories:
human-specific L1HS, primate-specific L1PA2-8, ancient
primate L1s, and ancient mammalian L1s. The EST se-
quences were aligned to full-length consensus sequences of
L1s in RepBase and those reported by Khan et al. [4] using
the LAST aligner (http://last.cbrc.jp/) [61]. For each EST
the position of the TSS was computed as a percentage
alignment position with respect to the full-length
consensus. YY1 transcription factor-binding sites in the 5’
UTR were identified by extracting the 5’ UTR sequence
from the L1HS consensus FASTA. The online tool JASPAR
Scan was used to identify YY1 binding sites corresponding
to two PWM for YY1 (MA0095.1 and MA0095.2) against
the first one kb 5’ UTR of the L1HS consensus using a rela-
tive score threshold of 90 % [29]. To create YY1 transcrip-
tion factor profiles, cell lines in the ENCODE project, for
which YY1 ChIP-seq was performed, were selected (for the
full list of publically available data, see Additional file 10:
Table S9). The YY1 ChIP-seq and input control reads were
aligned to the L1HS consensus sequence using bowtie1,
which is ideal for short reads <100 bp [62]. The log2FC en-
richment of YY1 was calculated per-base-pair of L1HS con-
sensus using the read coverage per million mapping reads
(RPM) of YY1 ChIP and input control, for which the nor-
malizing factor, total number of mapping reads in the li-
brary, was determined by separate alignment to the human
genome (build hg19). The raw log2FC YY1 enrichment
per-base-pair signal of L1HS consensus was smoothed by
applying LOESS smoothing with parameter α = 0.1.
To build TSS profiles of L1 ASP transcripts, we ob-
tained the TSS coordinate for L1PA2-8 and L1HS anti-
sense EST transcripts for plus-strand or minus-strand
ESTs. We downloaded alignment files from the EN-
CODE data repositories in BAM format (genome build
hg19, see Additional file 9: Table S8 for a complete list)
for the K562, H1-ESC, and Hela cell-lines and ChIP-seq
data for the H3K4me2 and H3K4me3 histone marks and
associated input controls. For K562 cells, we also down-
loaded alignments for YY1 ChIP-seq data and input con-
trols. The average ChIP enrichment of EST TSS for
plus- and minus-strand L1 ASP transcripts was calcu-
lated using Python package Metaseq using a genomic
window of +/−1000 bp TSS and a 100 bp bin size to cal-
culate depth [63]. The results for the plus and minus
strands were merged, where −1000 bp represented up-
stream of the TSS and +1000 bp downstream of the
TSS. The output of Metaseq was the input-subtracted
ChIP enrichment normalized as RPMs. The GRO-seq
data were analyzed in a similar manner (see Additional
file 10: Table S9 for a complete list); however, alignments
to the human genome (build hg19) were conducted
using BWA-MEM [64]. We used Samtools to separate
the positive-strand and minus-strand GRO-seq reads
and analyzed these reads against plus strand or minus
strand EST TSSs using Metaseq [65]. The results for the
plus- and minus-strand GRO-seq profiles were merged
to obtain normalized RPM enrichment.
Tissue specimens
For each specimen, we procured a single tissue frag-
ment, measuring ~ 1.0 × 0.5 × 0.5 cm, of selected grossly
unremarkable organs. All tissues were stored at −80°C.
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Validation of selected chimeric L1 ASP transcripts
We selected L1-UVRAG and L1-KIAA1324L chimeric
L1 ASP transcripts for validation. Using semi-
quantitative RT-PCR, we amplified a region across the
putative chimeric L1 ASP transcript that spans the L1
promoter and nearby exon. Half of the reaction (10 μl)
was resolved on a 2 % agarose gel to confirm the pres-
ence of a singular PCR product. The remainder of the
reaction was cloned using a TOPO TA Cloning Kit ac-
cording to the manufacturer’s specifications (Thermo
Fisher Scientific, Inc.; Wilmington, DE) and sequenced
via Sanger sequencing.
RNA isolation and cDNA synthesis
We originally yielded very small RNA amounts (<20 ng
RNA total) from fibrous organs, such as skin and muscle.
Therefore, we developed an in-house RNA isolation
method by modifying the protocol of an RNAeasy Plus
Mini Kit (Qiagen Sciences, Inc.; Germantown, MD). First, a
razor and forceps were used to finely mince one small tis-
sue fragment, weighing up to 50 mg, on dry ice. The
minced tissue fragments were suspended in 900 ml of PBS,
to which 100 μl of collagenase/dispase solution (stock at
10 mg/ml) was added. The solution was incubated at 37 °C
for 1 h. Then, the lysate was centrifuged for three (3) mi-
nutes at full speed using a bench-top centrifuge. The pellet
was collected and mixed with 10 μl of β-mercaptoethanol
and 1 ml of TRIzol reagent. The specimen on ice was ho-
mogenized using a hand-held homogenizer for 5 takes,
each entailing continuous homogenization for 1 min
followed by rest for 30 s. The specimen was incubated for
5 min at room temperature. Proteinase-K was then added
to a final concentration of 250 μg/ml (which came out to
12 μl of 20 mg/ml stock) and incubated at 56 °C for 10 min
[66]. The lysate was pipetted directly into a QIAshredder
spin column and centrifuged for 2 min at full speed. The
supernatant was collected into a gDNA Eliminator spin col-
umn; the specimen was centrifuged for 30 s at 8,000 x g,
and the flow-through was saved. The RNA precipitation
was initiated by adding 0.25 ml of chloroform to the super-
natant, and the specimen was shaken vigorously for 30 s.
The specimen was incubated at room temperature for
10 min, followed by centrifugation for 5 min at 12,000 x g
at 4 °C. The aqueous layer was separated, without touching
the middle layer (interface), and then mixed with 2 μl of
Pellet Paint NF Co-Precipitant reagent. 1 volume (usually
~200 μl) was mixed with ice-cold 70 % isopropanol into the
specimen, and precipitate was allowed to form for 10 min
at room temperature. The RNA was pelleted by centrifuga-
tion at maximum speed for 15 min, after which the super-
natant was removed carefully. The pellet was in 500 μl of
70 % ethanol, to remove as much of the overlying super-
natant as possible, and then air dried at room temperature
for approximately 5 min. Finally, the pellet was suspended
in 30–50 μl of RNASE-free deionized water and the RNA
was quantified via a NanoDrop 1000 Spectrophotometer
(Thermo Fisher Scientific, Inc.; Wilmington, DE). cDNA
were synthesized using poly-T primers according to the
manufacturer’s specifications (Roche Diagnostics; Basel,
Switzerland).
Quantitative real-time PCR
We estimated the relative abundance of targeted RNAs by
resulting traditional Cq (threshold cycle; quantitative
cycle) interval values in a StepOnePlus™ Real-Time PCR
System (Thermo Fisher Scientific, Inc.; Wilmington, DE).
Each experiment was performed in technical triplicates.
Actual PCR products were quantified with a FastStart
Universal SYBR Green probe (Roche Diagnostics; Basel,
Switzerland). The relative abundance of experimental
RNA—specifically, the arithmetic means of the Cq
values—was normalized to that of an internal control
RNA (GAPDH) to relative PCR efficiencies and pictorially
represented as Delta Cq (ΔCq) means ± standard devi-
ation. The PCR primers used in this report are in Add-
itional file 11: Table S10.
Conclusions
We identify 988 putative L1 antisense chimeric tran-
scripts, the vast majority of which are novel. We inde-
pendently verify some L1 antisense chimeric transcripts
using both bioinformatics analysis and empirical evi-
dence. Interestingly, some L1 antisense chimeric tran-
scripts are associated with evolutionarily ancient L1
subfamilies, suggesting exaptation of these
evolutionarily-older L1 sequences. We conclude that L1
antisense promoters contribute to the transcription of
up to 4% of all human genes and may potentially have
wide-ranging effects in health and disease.
Additional files
Additional file 1: Table S1. (excel) Summary of genomic screen result
identifying ESTs supporting putative L1 antisense promoter (ASP)
transcripts in the human genome (hg19). The 2015 ESTs are sometimes
represented more than once in Table S1 because a single EST can
overlap multiple cognate genes. (XLSX 276 kb)
Additional file 2: Supplementary figures 1–6 (PDF). Figure S1. Genomic
coordinates of 2015 ESTs supporting L1 ASP transcripts. A) ESTs
supporting L1 ASP transcripts from an evolutionarily ancient primate or
mammalian L1. B) ESTs supporting L1 ASP transcripts from an
evolutionarily recent human-specific L1HS or primate-specific L1PA2-8
subfamily. Figure S2: Evolutionary age of L1 subfamilies that contribute to
L1 ASP transcripts normalized by the RepeatMasker genomic frequencies
of L1 subfamilies. Figure S3: YY1 transcription factor binding at L1 ASP
transcripts displays two peaks. Binding profiles of YY1 at ESTs supporting
L1 ASP transcripts for A) L1-SNCAIP B) L1-KIAA1324L and C) L1-FOCAD.
The red indicates the positive strand and the blue indicates the negative
strand for the genome browser view. Figure S4: L1 ASP transcripts and
accompanying histone modification features in additional cell-lines. A-B)
The EST TSS enrichment profile of H3K4me2 and H3K4me3 ChIP-seq data
for L1PA2-8 and L1HS subfamilies in H1-ESC and Hela cell lines, respectively.
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The units for enrichment are input subtracted reads per million mapping
reads (RPM). C-D) The EST TSS enrichment profile of GRO-seq data for
L1PA2-8 and L1HS subfamilies in MCF7 and Hela cell-lines, respectively. The
units for enrichment are reads per million mapping reads (RPM). Figure S5:
Examples of L1 ASP transcripts that, despite displaying some evidence of L1
exonization, are likely to be L1 ASP transcripts. A) L1-MAPK10, which primarily
displays support for being classified a L1 ASP transcript and minor evidence of
L1 exonization. B) L1- SCAMP1, which displays non-overlapping independent
support for a L1 ASP transcript and L1 exonization. The red indicates the
positive strand and the blue indicates the negative strand for the genome
browser view. Figure S6: Genome browser view of conserved L1 ASP
transcripts identified in both mouse in human. The gene SHISA5 displays an
L1 ASP transcript originated from ancient shared mammalian L1M5
subfamilies. Conservation is displayed for various mammals including Rhesus,
Mouse, Rat, Rabbit, Pig, Dolphin, Dog, Elephant, Manatee, and Opossum where
dark vertical lines represent conservation. Mammals that contain the L1 ASP in
their genome are highlighted in red, whereas blue indicates absence of
contributing L1 ASP. (PDF 7039 kb)
Additional file 3: Table S2. (excel) Gene ontology analysis for 988
genes that we identified with associated L1 ASP transcripts using Panther
online database. (XLSX 11 kb)
Additional file 4: Table S3. (excel) Peptide identification for ESTs in
Table S1 using Transdecoder. Putative predicted peptides were
characterized for the presence of a stop codon and the ORF0 open
reading frame. (XLSX 197 kb)
Additional file 5: Table S4. (excel) YY1 binding site prediction in L1HS
consensus 5’ UTR using online tool JASPAR Scan. (XLSX 11 kb)
Additional file 6: Table S5. (excel) Validated Sanger sequences of L1
ASP transcripts L1-KIAA1324L and L1-UVRAG. (XLSX 11 kb)
Additional file 7: Table S6. (excel) Overlap between detected putative
L1 ASP transcripts from Table S1 and genes identified to play a causal
role in cancer (COSMIC database). (XLSX 18 kb)
Additional file 8: Table S7. (excel) Summary of ESTs supporting
putative L1 ASP transcript where an independent EST supported L1
exonization. These L1 ASP transcripts are considered to be potentially
explained by L1 exonization and are of lower confidence. (XLSX 187 kb)
Additional file 9: Table S8. (excel) Summary of mouse ESTs (mm10)
supporting putative L1 ASP transcripts. Filtering eliminated many putative
ESTs because unlike human ESTs much fewer mouse ESTs are labelled
with transcript direction information within the intronOrientation field.
The 307 ESTs represented in the table sometimes overlap more than one
gene and may be represented more than once. (XLSX 36 kb)
Additional file 10: Table S9. (excel) Summary of publicly available data
used for L1 ASP analysis. (XLSX 14 kb)
Additional file 11: Table S10. (excel) Primers used for empirical
validation of L1 ASP transcripts. (XLSX 9 kb)
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